Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant

Ophthalmology and Therapy

Volumn 4, Issue 1, 2015, Pages 51-58

  Bertelmann, Thomas ^a   Schulze, Stephan ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Diabetic macular edema; Fluocinolone acetonide; ILUVIEN ; Ocular coherence tomography; Visual acuity

Indexed keywords

BRINZOLAMIDE PLUS TIMOLOL; FLUOCINOLONE ACETONIDE; RANIBIZUMAB; VASCULOTROPIN ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CENTRAL MACULAR THICKNESS; DIABETIC MACULAR EDEMA; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; INTRAVITREAL IMPLANT; LASER COAGULATION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; VISUAL ACUITY;

EID: 85015582305     PISSN: 21938245     EISSN: 21936528     Source Type: Journal    
DOI: 10.1007/s40123-015-0028-0     Document Type: Article

References (11)

1. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014;10:CD007419.
2. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–32.
3. Messenger WB, Beardsley RM, Flaxel CJ. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. Drug Des Dev Ther. 2013;7:425–34.
4. Schwartz SG, Flynn HW Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol. 2011;12:347–51.
5. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–22.
6. Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120:583–7.
7. ®): in diabetic macular oedema. Drugs. 2013;73:187–93.
8. SmPC guidelines. https://www.medicines.org.uk/emc/medicine/27636. Accessed Nov 24, 2014.
9. ® implant for diabetic macular oedema—early case experiences. Eur Ophthalmic Rev. 2013;7:122–6.
10. ® prescribing information. Alimera Sciences, Inc. 6120 Windward Parkway, Alpharetta, GA 30005. http://www.alimerasciences.com/wp-content/uploads/2014/09/iluvien-prescribing-information.pdf. Accessed Jan 8, 2015.
11. Bron AM, Viswanathan AC, Thelen U, et al. International vision requirements for driver licensing and disability pensions: using a milestone approach in characterization of progressive eye disease. Clin Ophthalmol. 2010;4:1361–9.